ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HVO Hvivo Plc

28.60
0.10 (0.35%)
Last Updated: 13:07:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 0.35% 28.60 28.20 29.00 28.75 28.60 28.75 450,812 13:07:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 48.48M -776k -0.0011 -260.00 193.07M
Hvivo Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 28.50p. Over the last year, Hvivo shares have traded in a share price range of 14.15p to 31.00p.

Hvivo currently has 675,075,857 shares in issue. The market capitalisation of Hvivo is £193.07 million. Hvivo has a price to earnings ratio (PE ratio) of -260.00.

Hvivo Share Discussion Threads

Showing 2326 to 2348 of 9975 messages
Chat Pages: Latest  99  98  97  96  95  94  93  92  91  90  89  88  Older
DateSubjectAuthorDiscuss
30/11/2018
15:46
There she goes 35p next if Mr 10k keeps buys today
sparky333
30/11/2018
15:39
31p to buy soon. Get in quick this has legs
sparky333
30/11/2018
15:35
Snap back to 60p very quickly in no news.
sparky333
30/11/2018
15:34
Topped up.Rude not to!!!!
billthebank
30/11/2018
15:31
A dozen 10k buys in last hour
billthebank
30/11/2018
15:21
Just the beginning all the way to one pound!!!!
billthebank
30/11/2018
15:08
Nice rise for a friday afternoon, glad I bought a few at 25p earlier in the week :-)
azuli
28/11/2018
11:34
A wee rise like this every day till Xmas will do just fine
billthebank
28/11/2018
06:37
no it was a reflection of the dodgy shareprice action and pointing out the fact no one at the company is buying shares, just exercising a few cheapo options
mister md
27/11/2018
23:01
As Berny said, it's not the act of buying and selling, it's the subsequent writing of negative comments everyone you sell that is scummy.
discojames
27/11/2018
21:08
and when you see big sell at 20p followed by 50% rally to 30p you take some profits if you are trading
mister md
27/11/2018
21:00
to quote Buffett

rule #1 dont lose money
rule #2 dont forget rule #1

bernymadoff your hero by any chance?

mister md
27/11/2018
20:12
hardly gloating was it mon ami ? On a share like this I was happy with a 10% gain - might sell this current lot at your 50p+ average though. I like to buy and hold decent companies but occassionally trade dodgy Aim stuff like this one. The price activity here has been shocking and still intrigued by the massive sells at 20p
mister md
27/11/2018
20:02
People like you make me sick. Yesterday afternoon you were gloating over the fact that it had given up some of its gains from Friday.

Here's what you wrote:

"Hope everyone took their profits on the 23p shares from Friday ? I see the directors are all piling in to add to their tiny holdings ... or not ?"

Well your alleged buy price is not far off 23p and the directors haven't bought any shares. So what's with the volte face?

Don't mind people trading stocks but when they resort to deramping and trying to spook people into selling to get themselves a cheaper entry it really does take the biscuit.

bernymadoff
27/11/2018
18:52
back in with a few at 25p. Supply seems tight again. Nice 50k buy reported after close
mister md
27/11/2018
18:01
Thanks Mike for the update and lets hope the company does well not only for shareholders but jobs/economy in this brexit climate!!
joeblogg2
27/11/2018
17:46
Joe. As always buyer beware. Having said that, there are some fundamentals that look really good here. Essentially Hvivo is a service company providing testing facilities to big pharmaceuticals. They also have a couple of historical products in their portfolio through a joint venture with strong results so far. As a service company alone (which is their focus) they've recently won contracts and are looking to reduce costs and return to profitability next year. AIM companies that do this also do best on AIM. If the management stick to their vision then we should see something me real growth here. I'd expect the share price to yo-yo a bit as the short term investors buy and sell and take profit, probably in the 30s, and some mid term investors do the same around the 50 to 70 mark. After that long term investors will be looking at the £s. We're benefiting from a lack of shares in private investor hands at the moment and have just seen a sell off by a small institutional investor which has driven the price artificially low. A good time to buy, in my opinion. Any other thoughts anyone?
mikelmas10
27/11/2018
16:11
Tried to pick up a few of these yesterday but I couldn't get an online quote at the time. Picked up £5k's worth today instead, the 19,333 is my buy.
azuli
27/11/2018
16:03
Lots of new posters on here which is nice to see as it signals a return of positive sentiment and interest in the stock.

For their benefit this is the reason I'm invested here. There is the very real prospect of a major pharma paying a huge amount for Flu-v and maybe even the Ags-v anti malaria vaccine.

Plenty of examples of Biotechs selling P3 ready drugs following successful P2 for big money.

hxxps://www.fiercebiotech.com/biotech/arena-bags-big-deal-united-for-pah-drug-ralinepag

Yes you're reading it right. It's a $800m upfront payment with $400m milestones and double digit royalties. And this is for a drug targeting a market size forecast to be £8.7bn by 2025.

In contrast the market size for flu vaccines is expected to be $11.4bn by 2025.

Here's another example of a successful P2 drug being bought out by big pharma for mega bucks.

hxxp://www.bioworld.com/content/celgene-pay-nogra-710m-front-phase-iii-ready-crohn’s-therapy

The market for Crohn's Disease is substantially smaller at $4.7bn by 2025 but Nogra still got a $710m upfront payment.

Of course these deals take time to negotiate and many if not most PIs don't have the patience or the research background to hold for the best part of a year.

I've been adding down here and have now accumulated a handsome six figure holding.

Our CEO and the CEO of Imutex both have illustrious backgrounds which are both ideal for negotiating a great deal.and I have every confidence that in time they will deliver. Gregory Stoloff is a former investment banker who was responsible for arranging project finance for the major pharmas. HVO's CEO has formerly been Chief Operations Officer of a FTSE 250 company.

The macro climate is also favourable with governments and public health organisations throwing tens of millions of dollars into finding a universal flu vaccine.

The seller/shorter has provided an unexpected and once in a lifetime opportunity to get in at lows. Don't stare a gift horse in the mouth.

bernymadoff
27/11/2018
15:33
let's hope they say something new that day then!
qs99
27/11/2018
14:51
updated company ATTENDING world vaccine and immunotherapy congress
fromthesidelines
27/11/2018
14:44
company presenting in San Diego 28th to 30th November per website
fromthesidelines
27/11/2018
14:41
Welcome Joe, I think this is incredibly low risk at this price. Even our resident derampers can;t highlight any form of risk here. "Huge" number of contract negotiations happening at the moment and lots of cash in the bank, so no risk of a placement - what else is there to worry about?
discojames
Chat Pages: Latest  99  98  97  96  95  94  93  92  91  90  89  88  Older

Your Recent History

Delayed Upgrade Clock